Send to

Choose Destination

See 1 citation found by title matching your search:

Am Soc Clin Oncol Educ Book. 2016;35:e400-6. doi: 10.14694/EDBK_159010.

Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders.

Author information

From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.


Multiple myeloma (MM) is an incurable disease that progresses from a premalignant stage termed monoclonal gammopathy of undetermined significance (MGUS) and an intermediate stage of smoldering multiple myeloma (SMM). Recent major advances in therapy with more effective and less toxic treatments have brought reconsideration of early therapeutic intervention in management of SMM, with the goal of reducing progression of the disease before the occurrence of end-organ damage to MM and improving survival. Key to this effort is accurate identification of patients at high risk of progression who would truly benefit from early intervention. In this review, we discuss the current definitions, risk factors, risk stratification, prognosis, and management of MGUS and SMM, as well as new emerging therapeutic options under active investigation.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for American Society of Clinical Oncology
Loading ...
Support Center